11th week of 2010 patent applcation highlights part 38 |
Patent application number | Title | Published |
20100068106 | HYDROGEN PRODUCING APPARATUS - A hydrogen generating device including a temperature adjustment section | 2010-03-18 |
20100068107 | METHODS OF MAKING MICROFLUIDIC DEVICES AND DEVICES RESULTING - A method of making a microfluidic device by providing first and second substrates and forming a first frit structure on the first substrate and a second frit structure on the second substrate and consolidating the first and second substrates together, with frit structures facing, so as to form a consolidated-frit-defined and consolidated-frit-surrounded recess between said first and second substrates, where the second substrate has at least one pre-formed through-hole therein, and where forming a second frit structure includes forming a frit layer within said through-hole covering the interior surface of the through-hole to a thickness sufficiently thin to produce, on consolidating the substrates and the first and second frit structures together, a through-hole having an interior surface of consolidated frit continuous with the consolidated frit surrounding the recess. | 2010-03-18 |
20100068108 | COATED REACTORS, PRODUCTION METHOD THEREOF AND USE OF SAME - The present invention relates to a process for the preparation of primary di- and/or triamines of high purity from nitriles which can themselves originate from dimer and/or trimer acids. | 2010-03-18 |
20100068109 | Carbon Dioxide Sequestration Materials and Processes - The disclosure provides methods and systems for sequestering and/or reducing carbon dioxide present in an industrial effluent fluid stream containing carbon dioxide. A scrubbing material comprising a first component, a second component (distinct from the first component), and preferably water, is contacted with the effluent fluid stream. The first component comprises a source of calcium oxide and a source of alkali metal ions. The second component comprises a slag having one or more reactive silicate compounds. Methods of reducing carbon dioxide from exhaust generated by combustion sources, lime and/or cement kilns, iron and/or steel furnaces, and the like are provided. Carbon dioxide emission abatement systems are also disclosed. Methods of recycling industrial byproducts are further provided. | 2010-03-18 |
20100068110 | Removal of Hg, NOx, and SOx With Using Oxidants and Staged Gas/Liquid Contact - A method of scrubbing mercury compounds and nitrogen oxides from a gas stream employing a scrubbing operation. The method involves the contact of the stream which contains mercury, SO | 2010-03-18 |
20100068111 | Joining the mixing and variable gas atomizing of reactive chemicals in flue gas cleaning systems for removal of sulfur oxides, nitrogen oxides and mercury - Diverse methods of utilization and the corresponding, related modifications, of linear type, Variable Gas Atomization (VGA) nozzles and lances are described. Therein is joined the mixing and gas atomization of chemicals that react to form active products that further react with harmful flue gas constituents of combustion so as to enable their effective collection. One version combines, in a lance assembly of nozzles, the injection of reactants, in the form of finely divided dry solids conveyed in a carrier air stream, and the fine atomization of water, aqueous solutions or slurries. Atomization of such streams is employed to effectively wet the surfaces of the dry particles and, thereby, promote the rapid sorption of gaseous constituents of flue gas being treated. Another version simultaneously mixes and atomizes reacting chemicals to produce, and release into the flue gas stream, strongly oxidizing, transient, species of their reaction products. The simultaneous atomization and chemical reaction enables the effective capture of targeted flue gas constituents. An accompanying flue gas duct modification is described providing means for cost effective, high-performance system operation of linear VGA nozzle-lance arrays, as components of the various subject flue gas cleaning processes. The combination of linear VGA nozzle-lances and, as needed, flue gas duct enhancement, is intended to provide an economical and technically practicable means of retrofitting existing fossil fueled boilers of a wide range of capacities to meet future emission limits for SO | 2010-03-18 |
20100068112 | WIDE TEMPERATURE RANGE DIELECTRIC ABSORBER - According to one exemplary embodiment, a wide temperature range dielectric absorber includes a dielectric absorber comprising a blend of lanthanum oxide, strontium oxide, and cobalt oxide, and is represented by (1-z)[La | 2010-03-18 |
20100068113 | PHOSPHORUS RECOVERY - Phosphorous ions are extracted ( | 2010-03-18 |
20100068114 | METHODS FOR PREPARING SILICON GERMANIUM ALLOY NANOCRYSTALS - The present invention relates to a method of preparing silicon germanium alloy nanocrystals by the simultaneous thermal disproportionation of a siliceous material and GeX | 2010-03-18 |
20100068115 | SILICON RECLAMATION APPARATUS AND METHOD OF RECLAIMING SILICON - A silicon reclamation apparatus with which a large amount of silicon can be easily recovered from a waste slurry is provided. | 2010-03-18 |
20100068116 | METHOD AND APPARATUS FOR PREPARATION OF GRANULAR POLYSILICON - A process for preparing granular polysilicon using a fluidized bed reactor is disclosed. The upper and lower spaces of the bed are defined as a reaction zone and a heating zone, respectively, with the height of the reaction gas outlet being selected as the reference height. The invention maximizes the reactor productivity by sufficiently providing the heat required and stably maintaining the reaction temperature in the reaction zone, without impairing the mechanical stability of the fluidized bed reactor. This is achieved through electrical resistance heating in the heating zone where an internal heater is installed in a space in between the reaction gas supplying means and the inner wall of the reactor tube, thereby heating the fluidizing gas and the silicon particles in the heating zone. The heat generated in the heating zone is transferred to the reaction zone by supplying the fluidizing gas at such a rate that the silicon particles can be intermixed between the reaction zone and the heating zone in a continuous, fluidized state. | 2010-03-18 |
20100068117 | METHODS FOR PRODUCING GALLIUM AND OTHER OXO/HYDROXO-BRIDGED METAL AQUO CLUSTERS - Metallic clusters can be produced by contacting a metal salt such as a metal nitrate with an organic reducing agent. Metals can be selected from a group consisting of metals exhibiting octahedral coordination, and nitrates of the selected metal or metals are contacted with, for example nitrosobenzene. Binary, tertiary, or other clusters can be produced. | 2010-03-18 |
20100068118 | High-pressure vessel for growing group III nitride crystals and method of growing group III nitride crystals using high-pressure vessel and group III nitride crystal - The present invention discloses a high-pressure vessel of large size formed with a limited size of e.g. Ni—Cr based precipitation hardenable superalloy. The vessel may have multiple zones. | 2010-03-18 |
20100068119 | Process for Production of Hydrogen and Carbon Dioxide Capture - A process for removing CO | 2010-03-18 |
20100068120 | CATALYSTS FOR LOW TEMPERATURE OXIDATION OF CARBON MONOXIDE - CuO—ZnO—CeO | 2010-03-18 |
20100068121 | Method of Producing Xylitol Using Hydrolysate Containing Xylose and Arabinose Prepared from Byproduct of Tropical Fruit Biomass - Disclosed is a method of producing xylitol using a hydrolysate containing xylose and arabinose prepared from byproducts of tropical fruit biomass and more precisely, a method of producing xylitol which includes the steps of producing xylose and arabinose by the pretreatment of tropical fruit biomass byproducts including coconut shell, palm shell and oil palm empty fruit bunch (OPEFB) via acid (0.2-5%) hydrolysis and an electrodialysis and an ionic purification; and producing xylitol with high yield based on repeated batch fermentation using a hydrolysate containing xylose and arabinose as a carbon source. In addition, the present invention relates to an active carbon produced by carbonization and activation of a hydrolysate remainder of a tropical fruit shell, the byproduct of xylose and arabinose production, at a certain temperature and a preparation method of the same. | 2010-03-18 |
20100068122 | Gem Growth Cubic Press and Associated Methods - A multiple anvil press can be configured for gem-quality growth. The press can include a plurality of opposing anvils, where the anvils are configured for simultaneous movement within a tolerance of less than about 0.5 mm as measured at each anvil surface, and each anvil can be aligned to a common center of all the anvils where the alignment is tuned to a tolerance of less than about 0.1 mm during use. The press can also include a reaction volume formed by the enclosure of all anvils, where the reaction volume has a size configured to facilitate single crystal growth per cycle time. | 2010-03-18 |
20100068123 | Carbon nano-fibre production - This invention provides a reactor for carbon nano-fibre production comprising a generally horizontal elongate cylindrical reaction vessel arranged to rotate about its cylindrical axis and containing in use a particulate catalyst-containing reaction bed, said reaction vessel having a gas inlet port and a gas outlet port positioned such that one of said inlet and outlet ports is in said bed and the other is outside said bed. | 2010-03-18 |
20100068124 | NANOSTRUCTURE DEVICES AND FABRICATION METHOD - An ion flux is directed to a carbon nanotube to permanently shape, straighten and/or bend the carbon nanotube into a desired configuration. Such carbon nanotubes have many properties that make them ideal as probes for Scanning Probe Microscopy and many other applications. | 2010-03-18 |
20100068125 | METHOD OF REFINING CARBON PARTS FOR PRODUCTION OF POLYCRYSTALLINE SILICON - A method of refining carbon parts for the production of polycrystalline silicon, comprises the steps of, replacing an inside gas of a reactor, in which the carbon parts are placed, with an inert gas, drying the carbon parts by raising a temperature in the reactor to a drying temperature of the carbon parts while flowing an inert gas through the reactor, raising a temperature in the reactor to a purification temperature higher than the drying temperature while flowing chlorine gas through the reactor, reducing a pressure in the reactor, maintaining the inside of the reactor in a reduced pressure, pressurizing the inside of the reactor by introducing chlorine gas for bringing the inside of the reactor into a pressurized state, and cooling the inside of the reactor. | 2010-03-18 |
20100068126 | PROCESS FOR PRODUCING RUTHENIUM OXIDE-SUPPORTED MATERIAL AND PROCESS FOR PRODUCING CHLORINE - There are disclosed a process for producing a ruthenium oxide-supported material, characterized in that a ruthenium compound is supported on a titania carrier in which silica is supported on titania, and the obtained material is then calcined under an atmosphere of an oxidizing gas; and a process for producing chlorine by oxidizing hydrogen chloride with oxygen in the presence of the ruthenium oxide-supported material produced by the above-described process. | 2010-03-18 |
20100068127 | PROCESS FOR THE PRODUCTION OF SULPHURIC ACID - Process for the production of concentrated sulphuric acid and oleum from feed gases with up to 70% SO | 2010-03-18 |
20100068128 | REACTOR, AND METHOD FOR THE PRODUCTION OF HYDROGEN SULFIDE - The invention relates to a reactor ( | 2010-03-18 |
20100068129 | Synthesis of Aih3 and Structurally Related Phases - The present invention relates to a method for the preparation of material of the type AlH3 in one its structure modifications or structurally related aluminium containing hydrides. The invention also relates to a material prepared by this method. The invention also relates to uses of the material for reversible or irreversible hydrogen storage, for rocket fuel, pyrotechnic components, reduction agent, metal coating and polymerization catalyst, and as starting substance for making new metal hydrides. | 2010-03-18 |
20100068130 | Process for the Production of Hydrogen Gas Employing a Thermally Stable Catalyst - The present invention provides a process for producing a gaseous product comprising hydrogen, said process comprising: contacting a feed gas mixture comprising steam and a gas comprising from 1 to 5 carbon atoms with a catalyst structure under reaction conditions sufficient to produce the product gas comprising hydrogen, wherein the catalyst structure comprises: a metal substrate comprising a metal; at least one layer of a catalyst support material coated onto the metal substrate, wherein the catalyst support material comprises: θ-alumina, zirconia, and at least one rare earth metal oxide; and at least one catalytically active component, wherein the at least one catalytically active component is incorporated either into or onto the catalyst support material. | 2010-03-18 |
20100068131 | HYDROGEN PRODUCTION FROM FORMIC ACID - The present invention relates to a method of producing hydrogen gas and carbon dioxide in a catalytic reaction from formic acid, said reaction being conducted in an aqueous solution over a wide temperature range and already at room temperature (25° C.). The reaction is advantageous because it can be tuned to take place at very high rates, up to about 90 litre H2/minute/litre reactor volume. The gas produced is free of carbon monoxide. The method of the present invention is particularly suitable for providing hydrogen for a motor, fuel cell or chemical synthesis. | 2010-03-18 |
20100068132 | ARRAY OF PLANAR MEMBRANE MODULES FOR PRODUCING HYDROGEN - A shared or common environment membrane reactor containing a plurality of planar membrane modules with top and bottom thin foil membranes supported by both an intermediary porous support plate and a central base which has both solid extended members and hollow regions or a hollow region whereby the two sides of the base are in fluid communication. The membrane reactor operates at elevate temperatures for generating hydrogen from hydrogen rich feed fuels. | 2010-03-18 |
20100068133 | TWO-STAGE REFORMER AND METHOD FOR OPERATING A REFORMER - The invention relates to a reformer for converting fuel and oxidising agent into a reformate, the reformer comprising an oxidising zone to which a mixture of fuel and oxidising agent is supplyable via a first fuel supply and a first oxidising agent supply and an injection and mixture formation zone disposed downstream of the oxidising zone to which further fuel is supplyable via a second fuel supply, a second oxidising agent supply being provided via which further oxidising agent is supplyable to the injection and mixture formation zone. According to the invention it is contemplated that the second oxidising agent supply is, relative to the second fuel supply, arranged so that it generates a barrier oxidising agent cushion in the area in front of the second fuel supply to prevent a heat transfer from the mixture from the oxidising zone to the second fuel supply. The invention further relates to a method for operating such a reformer. | 2010-03-18 |
20100068134 | METHODS OF ENHANCING KINETIC PROPERTIES OF HYDROGEN STORAGE MATERIALS BY SELF-CATALYSIS - Methods of enhancing the kinetic properties of solid-state hydrogen storage materials are disclosed. The methods of the present invention comprise a process of utilizing built-in, ancillary reactions to effectually catalyze primary hydrogen storage reactions. This self-catalysis process gives rise to novel mechanisms for solid-state hydrogen storage compositions that benefit from enhanced kinetic properties, thereby increasing the usefulness of hydrogen storage technologies. The methods of enhancing the kinetic properties of hydrogen storage compositions by implementing a self-catalyzing reaction mechanism generally include formulating a hydrogen desorption pathway in a hydrogen storage composition, the pathway including a hydrogen releasing reaction and an ancillary reaction; and selecting the ancillary reaction to produce a product that serves to enhance the kinetic properties of the hydrogen releasing reaction. | 2010-03-18 |
20100068135 | ANTIBODY COMPOSITIONS, METHODS FOR TREATING NEOPLASTIC DISEASE AND METHODS FOR REGULATING FERTILITY - Antibody compositions and methods for inhibition of the effects of gonadotropin hormones are provided. Methods for treating cancer and methods for regulating fertility are provided by administration of the antibody compositions to a mammalian subject in need thereof. | 2010-03-18 |
20100068136 | Anti-CD19 Antibodies - The present invention provides humanized, chimeric and human anti-CD19 antibodies, anti-CD19 antibody fusion proteins, and fragments thereof that bind to a human B cell marker. Such antibodies, fusion proteins and fragments thereof are useful for the treatment and diagnosis of various B-cell disorders, including B-cell malignancies and autoimmune diseases. In more particular embodiments, the humanized anti-CD19 antibodies may comprise one or more framework region amino acid substitutions designed to improve protein stability, antibody binding and/or expression levels. In a particularly preferred embodiment, the substitutions comprise a Ser91Phe substitution in the hA19 VH sequence. | 2010-03-18 |
20100068137 | Dock-and-Lock (DNL) Vaccines for Cancer Therapy - The present invention concerns methods and compositions for forming anti-cancer vaccine DNL complexes using dock-and-lock technology. In preferred embodiments, the anti-cancer vaccine DNL complex comprises an antibody moiety that binds to dendritic cells, such as an anti-CD74 antibody or antigen-binding fragment thereof, attached to an AD (anchoring domain) moiety and a xenoantigen, such as CD20, attached to a DDD (dimerization and docking domain) moiety, wherein two copies of the DDD moiety form a dimer that binds to the AD moiety, resulting in the formation of the DNL complex. The anti-cancer vaccine DNL complex is capable of inducing an immune response against xenoantigen expressing cancer cells, such as CD138 | 2010-03-18 |
20100068138 | STRUCTURALLY RIGID DOPAMINE D3 RECEPTOR SELECTIVE LIGANDS AND PROCESS FOR MAKING THEM - A family of structurally rigid dopamine D3 receptor selective ligands is described. The family of structurally rigid dopamine D3 receptor selective ligands has the formula wherein A is cis or trans —CH═CH—, —C═C—, or cyclohexyl. B is cis or trans —CH═CH— or absent. R1 represents an optionally substituted phenyl group, wherein said substituents are selected from the group consisting of: hydrogen, halogen, amino, nitro, hydroxyl, alkoxy, alkyl, acyl and pyridyl, and said substitution may occur at any of the ortho, meta, or para positions, or R1 represents a heteroaromatic ring. A preferred heteroaromatic ring is indole, quinoxoline, pyridyl, pyrimidyl, or imidazole. R2 and R3 may be independently hydrogen or a halogen, or R2 alone may be C1, C2, or C3 alkoxy, and m is 1 or 2, and n is 0, 1, or 2. | 2010-03-18 |
20100068139 | Methods of radiofluorination of biologically active vectors - The invention relates to conjugates of formula (V) or (VI): wherein X is —CO—NH—, —NH—, —O—, —NHCONH—, or —NHCSNH—; their use as radiopharmaceuticals, processes for their preparation, and synthetic intermediates used in such processes. | 2010-03-18 |
20100068140 | MYELIN DETECTION USING BENZOFURAN DERIVATIVES - The present invention relates to methods for the detection of myelin and a quantitative measurement of its local concentration in a sample using a benzofuran compound or its radioisotope derivatives. In one embodiment a method of myelin detection comprises identifying a subject at risk of or diagnosed with a myelin-associated neuropathy, parenterally administering to the subject the benzofuran compound, or a derivative of the compound, and determining myelination in the subject by detecting binding in the sample. In one embodiment, the invention provides a method of imaging myelinated tissue in a surgical field of mammalian tissue comprising the steps of contacting the surgical site with the benzofuran compound or a radioisotope derivative of the compound, and detecting binding in the surgical site. In yet another embodiment, a method of imaging spinal cord and spinal nerve root tissue is provided comprising the steps of parenteral administration of a radioisotope derivative of the benzofuran compound and detecting the radioisotope derivative within the spinal canal and intervertebral foramen. Methods of quantification of binding of the benzofuran compound or its derivatives are also provided. | 2010-03-18 |
20100068141 | USE OF HEAT SHOCK TO TREAT OCULAR DISEASE - The invention generally provides methods for recruiting stem cells to an ocular tissue. The methods involve inducing heat shock in the ocular tissue using a subthreshold laser and/or an agent. In some embodiments, the heat shock is induced following the administration of an agent that mobilizes HSCs. | 2010-03-18 |
20100068142 | MELANOMA REPOPULATING CELLS - The invention relates to the identification of melanoma repopulating cells, characterization of these cells, and diagnostic and therapeutic methods based on an understanding of the properties of these cells. | 2010-03-18 |
20100068143 | METAL-POLYMER COORDINATION COMPLEX INCORPORATING PHOSPHORUS ATOMS AND APPLICATIONS USING SUCH A COMPLEX - The invention relates to a compound comprising at least one polymeric chain incorporating phosphorus atoms and consisting, in all or in part, of identical or different repeated units, each of said units being represented by the following formula: | 2010-03-18 |
20100068144 | NONLINEAR OPTICAL DETECTION OF MOLECULES COMPRISING AN UNNATURAL AMINO ACID POSSESSING A HYPERPOLARIZABILITY - A system for making molecules, and proteins in particular, suitable for detection by a surface-selective nonlinear optical technique. A first use of the invention is for determining a protein's structure in real space and real time. A second use of the invention is to detect a protein or its activity (conformational change). A third use of the invention is for drug screening. A further aspect of the present invention is measuring probe tilt angle orientation in an oriented protein. | 2010-03-18 |
20100068145 | Bispecific fusion protein having therapeutic and diagnostic potential - The present invention relates to a bispecific fusion protein, comprising (a) a first polypeptide which binds to collagen, and (b) a second polypeptide which binds to endothelial precursor cells. Also, pharmaceutical compositions are disclosed, comprising the fusion protein of the invention, as well as methods for using the fusion protein, in particular for treating or preventing lesions of vessels and tissues. | 2010-03-18 |
20100068146 | Method for Improving Brain Fitness with Consumable Products - The present invention is directed to a method for improving brain fitness. The method includes the step of providing non-protein amino acid to a consumer prior to playing a brain game. | 2010-03-18 |
20100068147 | DENGUE DIAGNOSIS AND TREATMENT - We describe a method of providing an indication useful in the diagnosis or prognosis of dengue, the method comprising detecting a change in the expression pattern or level of: (a) a ubiquitin-proteasome pathway protein; (b) a interferon-related protein; or (c) an NF-κB-mediated cytokine/chemokine response protein. We also describe a method of identifying a molecule suitable for the treatment or prevention of dengue, the method comprising determining if a candidate molecule is an agonist or antagonist of any one or more of these proteins. | 2010-03-18 |
20100068148 | ENHANCED RESOLUTION OF TUMOR METASTASIS USING A SKIN FLAP MODEL - A enhanced method for observing tumor progression, angiogenesis and/or metastasis in animal models in real time is described. The invention employs a skin flap over the area to be observed that can be opened and closed reversibly. The invention also permits simultaneous observation of more than one tumor by use of multiple colors. | 2010-03-18 |
20100068149 | Use of nutritional compositions for preventing disorders - The present invention relates to a method for preventing and/or treating visceral adiposity and/or to alter body fat distribution by administering a certain nutritional composition to a human subject with the age between 0 and 48 months, and preventing the occurrence of diseases later in life. | 2010-03-18 |
20100068150 | Selective Caspase Inhibitors - Described here are novel, highly selective inhibitors and activity based probes (ABPs) for caspases 3, 7, 8, and 9 and legumain. The compounds selectively inhibit only certain caspases. A positional scanning combinatorial library (PSCL) approach was used to screen pools of peptide acyloxymethyl ketones (AOMKs) containing both natural and non-natural amino acids for activity against a number of purified recombinant caspases. These screens were used to identify structural elements at multiple positions on the peptide scaffold that could be modulated to control inhibitor specificity towards target caspases. Further disclosed are individual optimized covalent inhibitors that could also be equipped with various tags for use as activity based probes, as well as labeled substrates. | 2010-03-18 |
20100068151 | MULTIMODALITY MOLECULAR IMAGING WITH THERAPEUTIC CONJUGATES - Disclosed are pharmaceutical compounds comprising a cell-specific targeting moiety, an anti-cell proliferation moiety, and a chelator moiety. Also disclosed are methods for treating a subject with a hyperproliferative disease, methods for diagnosing presence of a hyperproliferative disease in a subject, and methods for detecting a therapeutic response in a subject that employ the pharmaceutical compounds of the present invention. | 2010-03-18 |
20100068152 | Ex vivo modifiable particle or polymeric based final dosage form - Provided embodiments include a final dosage form, an article of manufacture, and method. A final dosage form for administering a medicament to an animal is provided. The final dosage form includes the medicament, and a particle or polymeric material. The particle or polymeric material carries the medicament and is configured in a medicament-retention state. In medicament-retention state, the medicament is substantially not bioavailable to the animal if the final dosage form is administered to the animal. The particle or polymeric material is modifiable ex vivo by an exposure to a stimulus to a medicament-release state. In the medicament-release state, the medicament is substantially bioavailable to the animal if the final dosage form is administered to the animal. | 2010-03-18 |
20100068153 | Ex vivo activatable final dosage form - Provided embodiments include a final dosage form, an article of manufacture, and method. A final dosage form for administering a medicament to an animal is provided. The final dosage form includes an outer layer, the medicament, and a release element. The release element configured in a medicament-holding state and modifiable ex vivo to a medicament-discharge state by an exposure to a stimulus. In an embodiment, the final dosage form includes a chamber substantially within the outer layer and carrying the medicament. In an embodiment, the final dosage form includes an indicator element configured to indicate an exposure of the release element to the stimulus. | 2010-03-18 |
20100068154 | Printable Igniters - An igniter comprises at least two conductors in the spaced-apart configuration and an electrically conductive layer bridging the at least two conductors, wherein the conductive layer has an electrical resistance greater than an electrical resistance of the at least two conductors. In one embodiment, the at least two conductors and the electrically conductive layer comprise a conductive ink, which may be the same conductive ink having different dimensions. A supplementary initiator composition may be deposited on or incorporated into the conductive layer. In a process for producing the igniter, the electrically conductive layer and the at least two conductors are printed on a non-electrically conducting substrate. Also disclosed are a method for igniting a combustible composition using the igniter, a method for producing an aerosol drug using the igniter, a method for providing a dose of a drug to a human patient using the igniter, a drug delivery device comprising the igniter and a drug supply unit comprising the igniter. | 2010-03-18 |
20100068155 | Reactant Formulations and Methods for Controlled Heating - Disclosed herein are reactant formulations capable of undergoing an exothermic chemical reaction. The reactant formulations comprise a metal reducing agent, a metal-containing oxidizing agent, and manganese oxide in an amount effective to control a temperature profile of the reactant formulation. The manganese oxide may be, for example and without limitation, MnO, MnO | 2010-03-18 |
20100068156 | AMPHOLYTIC COPOLYMER BASED ON QUATERNIZED NITROGEN-CONTAINING MONOMERS - The present invention relates to an ampholytic copolymer based on quaternized nitrogen-containing monomers which has a molar excess of cationogenic/cationic groups compared to anionogenic/anionic groups, to cosmetic or pharmaceutical compositions which comprise at least one such ampholytic copolymer, and to further uses of these copolymers. | 2010-03-18 |
20100068157 | ORAL COMPOSITIONS, THEIR PREPARATION AND USE - An oral composition having a pH in the range of from 3 to 8.5, comprising: (a) in the range of from 0.1% to <10% w/w (based on the total weight of the oral composition) of a stock solution comprising a mixture of bioflavonoids and fruit acids or salts thereof; and (b) water; and, optionally, (c) a pharmaceutically acceptable carrier therefor. | 2010-03-18 |
20100068158 | Cleansing Composition - The present invention relates to a cleansing composition comprising an anti-microbial agent and a sulphur binding and/or oxidising agent, and wherein the pH of the composition is 7 or lower, to a method for preparing the cleansing composition and its use. | 2010-03-18 |
20100068159 | FUNCTIONALIZED CALCIUM PHOSPHATE HYBRID SYSTEMS FOR CONFECTIONERY AND FOODSTUFF APPLICATIONS - A method of whitening teeth, including an application of functionalized calcium phosphate additives generated via a solid-state method. The additives were produced by placing predetermined amounts of inorganic and inorganic materials and milling media into a vessel rotatably connected to a turntable platform, an amount of an organic material into the vessel, rotating the vessel in a first direction while turning the turntable platform in a second direction counter to the first direction, with the resultant material defining the functionalized calcium phosphate. The inorganic material may include calcium phosphates of varying phases, structure, and composition. The organic material may include anionic surfactants, cationic surfactants, neutral surfactants, carboxylic acids, polymers, copolymers, block copolymers, and combinations thereof. Once produced, the additives were added to comestibles, such as in confectionery and foodstuff formats, for delivery to the teeth and dental structures. | 2010-03-18 |
20100068160 | COSMETIC AND DERMATOLOGICAL FORMULATIONS INCLUDING PHENOXYALKYL ESTERS - The invention relates to the use of phenoxyalkyl esters of C | 2010-03-18 |
20100068161 | TOPICAL COMPOSITION FOR THE PROTECTION AND/OR TREATMENT OF RADIATION RELATED SKIN DAMAGES - There is provided a topical composition for the protection and/or treatment of radiation related skin damages comprising from 18.4% to 68% by volume of active principles comprising anti-oxidants, moisturizers, humectants, emollients, anti-inflammatory agents, healing promoting agents and dermal circulation enhancers in from 81.6% to 32% by volume of a pharmaceutically acceptable carrier. | 2010-03-18 |
20100068162 | Compositions Having Silicone Properties - Silicone-free, carbon-based replacements for volatile silicones, such as cyclomethicones, are disclosed. The compositions can be used as is or in dermatological products. | 2010-03-18 |
20100068163 | Keratin Fibre Coating Composition Comprising a Liquid Fatty Phase and a Tackifying Resin - The present invention relates to a keratin fibre coating composition comprising a cosmetically acceptable liquid medium comprising a liquid fatty phase and at least one resin chosen from rosins, rosin derivatives and hydrocarbon-based resins, and mixtures thereof, the said resin having a number-average molecular weight of less than or equal to 10 000 and a particular lipophilic gelling agent. The invention also relates to the use of such a composition to obtain a smooth, uniform deposit on keratin fibres and a film that shows good resistance to water and to rubbing. | 2010-03-18 |
20100068164 | METHOD FOR INHIBITING FADING AND ENHANCING COLOR INTENSITY OF COLOR-TREATED HAIR - The invention provides a method for inhibiting color fading in color-treated keratinous fibers, which method includes treating the keratinous fibers with a color-fade inhibiting-effective effective amount of a monoalkyl quaternary ammonium salt. The invention also provides a method for enhancing the intensity of color in color-treated keratinous fibers, which method includes treating the keratinous fibers with a color intensity enhancing effective amount of an alkyl a quaternary ammonium salt. Additionally provided are products for inhibiting the fading of color and increasing the intensity of color in color-treated keratinous fibers. | 2010-03-18 |
20100068165 | DETERGENT COSMETIC COMPOSITIONS COMPRISING AT LEAST ONE AMINO SILICONE, AND USES THEREOF - The disclosure relates to novel detergent compositions comprising, in a cosmetically acceptable medium, at least one sulfate or sulfonate anionic surfactant, at least one amphoteric and/or zwitterionic surfactant and at least one particular amino silicone, the (amphoteric and/or zwitterionic surfactant)/(sulfate or sulfonate anionic surfactant) weight ratio ranging from 1:1 to 2:1, the total amount of surfactants representing from 4% to 35% by weight relative to the total weight of the final composition. The disclosure also relates to the use of the composition for protecting the coloration of, for example, artificially dyed hair. | 2010-03-18 |
20100068166 | ORAL COMPOSITION COMPRISING DIMETHICONE COPOLYOL - Oral compositions comprising silicone polyols are described for lubricating and hydrating the buccal cavity and are of benefit in alleviating the symptoms of xerostomia (dry mouth). | 2010-03-18 |
20100068167 | Low Salt Forms of Polyallylamine - Disclosed is a pharmaceutical composition comprising a stable polyallylamine hydrochloride polymer in which between about 4% to about 12% by weight of the polymer is a chloride anion and a pharmaceutically acceptable carrier or diluent. | 2010-03-18 |
20100068168 | THERMAL RESPONSIVE POLYMER SILOXANES, COMPOSITIONS, AND METHOD AND APPLICATIONS RELATED THERETO - The invention relates to materials comprising siloxanes, preferably the materials have thermal-responsive properties. In some embodiments, the invention relates to silsesquioxane groups functionalized with polymers. In another embodiment, silsequioxane-polymer conjugates comprise polylactone segments. The silsequioxane-polymer conjugates may be crosslinked together to form a material, and these materials may be functionalized with bioactive compounds so that the materials have desirable biocompatibility or bioactivity when used in medical devices. In further embodiments, the invention relates to composite materials that contain a polymer matrix and aggregates, and in some embodiments, methods of making, and methods of using these materials. Preferably, the aggregates are calcium phosphate aggregates. Preferably, the material is resistant to fracture. In further embodiments, the materials are used in surgical procedures of bone replacement. In further embodiments, the materials contain polyhedral silsesquioxanes and/or biodegradable segments. | 2010-03-18 |
20100068169 | MONOLITHIC DRUG DELIVERY SYSTEM - This invention relates to an improved monolithic drug delivery dosage form which releases a pharmaceutically active agent at a predetermined rate. The dosage form comprises a salted-out or crosslinked polymer and a pharmaceutically active agent. The salted-out or crosslinked polymer functions to polymerically entangle the pharmaceutically active agent but, progressively relax on contact with an aqueous medium in use to release the pharmaceutically active agent at a predetermined rate. | 2010-03-18 |
20100068170 | LOCAL DELIVERY OF WATER-SOLUBLE OR WATER-INSOLUBLE THERAPEUTIC AGENTS TO THE SURFACE OF BODY LUMENS - A method and device for local delivery of water-soluble or water-insoluble therapeutic agents to the surface of a normal or diseased body lumen is disclosed. An expandable structure of a medical disposable device, such as a balloon of a balloon catheter, is coated with an amphiphilic polymer coating comprising a therapeutic agent and an amphiphilic polymer or co-polymer. The medical disposable device is inserted into a body lumen, and expanded to contact the amphiphilic polymer coating against the body lumen. The total solubility of the polymer or co-polymer in vivo prevents any embolic hazard associated with the amphiphilic polymer coating. | 2010-03-18 |
20100068171 | INJECTABLE BONE/POLYMER COMPOSITE BONE VOID FILLERS - A biodegradable polyurethane scaffold that includes a HDI trimer polyisocyanate and at least one polyol; wherein the density of said scaffold is from about 50 to about 250 kg m−3 and the porosity of the scaffold is greater than about 70 (vol %) and at least 50% of the pores are interconnected with another pore. The scaffolds of the present invention are injectable as polyurethane foams, and are useful in the field of tissue engineering. | 2010-03-18 |
20100068172 | Nematode Control - The present invention concerns methods for controlling nematode infestation via dsRNA mediated gene silencing, whereby the intact nematodes are contacted with a double-stranded RNA and whereby the double-stranded RNA is taken up by the intact nematodes. In one particular embodiment, the methods of the invention are used to alleviate plants from nematode pests. Alternatively, the methods are used for treating and/or preventing nematode infestation on a substrate or a subject in need of such treatment and/or prevention. Suitable nematode target genes and fragments thereof, dsRNA constructs, recombinant constructs and compositions are disclosed. | 2010-03-18 |
20100068173 | Recombinant Human Albumin-Interleukin-11 Fusion Protein With Long-Lasting Biological Effects - Compositions, kits and methods are provided for promoting general health or for prevention or treatment of diseases by using novel recombinant fusion proteins of human serum albumin (HSA) and bioactive molecules. The bioactive molecules may be a protein or peptide having a biological function in vitro or in vivo, and preferably, having a therapeutic activity when administered to a human. By fusing the bioactive molecule to HSA, stability of the bioactive molecule in vivo can be improved and the therapeutic index increased due to reduced toxicity and longer-lasting therapeutic effects in vivo. In addition, manufacturing processes are provided for efficient, cost-effective production of these recombinant proteins in yeast. | 2010-03-18 |
20100068174 | COMBINATION WITH BIS (THIOHYDRAZIDE AMIDES) FOR TREATING CANCER - Disclosed herein are methods of treating an immunosensitive cancer with bis(thio-hydrazide amides) or pharmaceutically-acceptable salts thereof and an immunotherapy. | 2010-03-18 |
20100068175 | Methods of using Fc-Cytokine fusion proteins - Disclosed herein are methods and compositions for enhancing the immunogenicity of a preselected protein or peptide antigen in a mammal. Immunogenicity is enhanced by fusing the preselected antigen to an immunoglobulin heavy chain constant region to produce an Fc-antigen fusion protein. The Fc-antigen fusion proteins bind Fc receptors on the surface of antigen presenting cells, thereby targeting the antigen to the antigen presenting cells in the mammal. In addition, disclosed is a family of adjuvants, for example, an Fc-adjuvant fusion protein, for use in combination with the Fc-antigen fusion proteins to enhance or modulate a particular immune response against the preselected antigen. | 2010-03-18 |
20100068176 | HEPATITIS C VIRUS INHIBITORS - The present disclosure relates to compounds, compositions and methods for the treatment of Hepatitis C virus (HCV) infection. Also disclosed are pharmaceutical compositions containing such compounds and methods for using these compounds in the treatment of HCV infection. | 2010-03-18 |
20100068177 | METHODS OF ORGAN REGENERATION - The invention features methods for increasing or maintaining the number of functional cells of a predetermined type in a mammal (e.g., a human patient), for example, the insulin producing cells of the pancreas, liver cells, spleen cells, or bone cells, that has injured or damaged cells of the predetermined type or is deficient in cells of the predetermined type. | 2010-03-18 |
20100068178 | ANTI-CANCER DRUGS AND USES RELATING THERETO FOR METASTATIC MALIGNANT MELANOMA AND OTHER CANCERS - The present invention discloses triazene analogs of the general formula (I) and formula (II), their tautomeric forms, stereoisomers, polymorphs, hydrates, solvates, and pharmaceutically acceptable salts thereof for the metastatic malignant melanoma and other cancers including but not limited to lymphomas, sarcomas, carcinomas, and gliomas. | 2010-03-18 |
20100068179 | Phosphohalohydrins, Process For The Production Thereof And Use Thereof - The invention provides compounds comprising at least one phosphohalohydrin group of the formula: | 2010-03-18 |
20100068180 | NOVEL METHODS FOR MODULATING INFLAMMATORY AND/OR IMMUNE RESPONSES - The invention is directed to novel methods for modulating inflammatory and/or immune responses. Such methods utilize compositions comprising extraembryonic cells (herein referred to as EE cells) including but not limited to extraembryonic HLA-G positive cells (herein referred to as EHP cells) and amnion-derived multipotent progenitor cells (herein referred to as AMP cells); compositions comprising expanded EE cell populations, and/or cell lysates and/or conditioned media derived therefrom, alone or in combination with each other and/or in combination with various extracellular matrices and/or devices and/or other suitable active agents. | 2010-03-18 |
20100068181 | PYRROLO [3, 2-A] PYRIDINE DERIVATIVES FOR INHIBITING KSP KINESIN ACTIVITY - The present invention provides compounds of Formula I (wherein R, R | 2010-03-18 |
20100068182 | COMBINATION THERAPY FOR TREATING HCV INFECTION - The present invention relates to therapeutic combinations comprising (a) Compound (1), or a pharmaceutically acceptable salt thereof, as herein described, (b) an interferon alfa and (c) ribavirin. Compound (1) is a selective and potent inhibitor of the HCV NS3 serine protease. The present invention also relates to methods of using such therapeutic combinations for treating HCV infection or alleviating one or more symptoms thereof in a patient. | 2010-03-18 |
20100068183 | Methods of treating lysosomal storage related diseases by gene therapy - Isolated nucleic acid-based vectors and lentivirus vectors, and methods of using those vectors to inhibit or prevent metabolic disorders in a mammal, are provided. | 2010-03-18 |
20100068184 | LIVING BODY HEALING ACCELERATOR - The present invention provides a living body healing, having an accelerating activity in the regeneration ability relating to the cure of damages of cells or tissues caused by toxicity of a drug or a wound in a living body, having high safety, and also not causing any side effect even administered for a long period of time. Problems are solved by a living body healing accelerator containing as an active constituent a mixture of a culture solution obtained after cultivation of a microorganism belonging to the | 2010-03-18 |
20100068185 | METHODS FOR INTRODUCING BACTERIOPHAGE INTO THE INTERIORS OF QUANTITIES OF EDIBLE AGRICULTURAL PRODUCTS AND EDIBLE AGRICULTURAL PRODUCTS WITH PHAGE-CONTAINING PREPARATIONS IN THE INTERIORS THEREOF - Methods for treating foods with bacteriophage include introducing, or incorporating, bacteriophage into the interiors of edible agricultural products, such as ground meats, milled grains, and other ground, cut, or processed edible agricultural products, or solid edible agricultural products. The phage, or a phage-containing preparation of which the phage is a part, may be dispersed throughout the edible agricultural product. Such dispersal may be substantially homogenous. The introduction of phage into the interior of a quantity of an edible agricultural product is useful for controlling bacterial populations in the edible agricultural product. | 2010-03-18 |
20100068186 | High affinity telomerase t cell receptors - The present invention provides T cell receptors (TCRs) having the property of binding to ILAKFLHWL-HLA-A*0201 and comprising at least one TCR α chain variable domain and/or at least one TCR β chain variable domain CHARACTERISED IN THAT said TCR has a K | 2010-03-18 |
20100068187 | TRANSCRIPTION FACTORS FOR DIFFERENTIATION OF ADULT HUMAN OLFACTORY PROGENITOR CELLS - A method of transplantation that includes lineage priming human progenitor cells, to form lineage primed cells and transplanting the lineage primed cells into a patient. The lineage primed cells are selected from the group consisting of oligodendrocytic lineage primed cells, dopaminergic lineage primed cells, and motoneuronal lineage primed cells, and lineage priming has an efficiency of at least 1%. | 2010-03-18 |
20100068188 | COMPOSITION FOR REGENERATION OF PERIODONTAL HARD TISSUE AND METHOD FOR REGENERATION OF PERIODONTAL HARD TISSUE - An object of the present invention is to provide technology of using a preadipocyte to restore comprehensively bone, cartilage and periodontal ligament, and cause a periodontal hard tissue to regenerate. By culturing a preadipocyte using a culture medium containing (i) at least one member selected from the group consisting of glycerophosphate and salts thereof, and (ii) at least one member selected from the group consisting of ascorbic acid, derivatives thereof and salts thereof and not containing an adrenal cortical hormone in such an amount that promotes differentiation of a preadipocyte into a periodontal hard tissue cell, differentiation of the cell into a periodontal hard tissue cell is induced efficiently. Furthermore, a scaffold is combined with the preadipocyte cultured with the above-mentioned culture medium to be transplanted into a periodontal tissue that requires regeneration. | 2010-03-18 |
20100068189 | Method for Expanding Adult Stem Cells from Blood and Compositions and Methods for Using the Same - A method for the expansion of adult stem cells from blood, particularly but not only peripheral blood, involves removing adult stem cells from blood of a mammal, immediately expanding the stem cells via in-vitro treatment with MCSF (Macrophage Colony Stimulating Factor) at a concentration of about 8-15 nM, and purifying the expanded stem cells. Compositions and methods of using the expanded adult stem cells are also described. | 2010-03-18 |
20100068190 | MESOANGIOBLAST-LIKE CELL AS WELL AS METHODS AND USES RELATING THERETO - The present invention relates to a medicament comprising a mesoangioblast-like cell obtained from a subject, a method of isolating a mesoangioblast-like cell, a method of producing a mesoderm-derived cell using a mesoangioblast-like cell, the use of a mesoangioblast-like cell for the preparation of a medicament for treating a cardiovascular disease and/or an ischemic disease and a method of converting the mesoangioblast-like cell into a pluripotent stem cell. | 2010-03-18 |
20100068191 | PURIFIED MESENCHYMAL STEM CELL COMPOSITIONS AND METHODS OF PURIFYING MESENCHYMAL STEM CELL COMPOSITIONS - One or more purified mesenchymal stem cell pharmaceutical compositions and methods of manufacture utilizing centrifugal filtration are disclosed. Threshold limits for intravenous administration of mesenchymal stem cell pharmaceutical compositions comprising residual animal products are also disclosed. | 2010-03-18 |
20100068192 | Method for Production of T Cell Population - A method for preparing a T cell population, wherein the T cell population expresses CD45RA and expresses at least one selected from the group consisting of CD62L, CCR7, CD27, and CD28, characterized in that the method comprises the step of culturing a cell population comprising a T cell, in the presence of fibronectin, a fragment thereof or a mixture thereof. | 2010-03-18 |
20100068193 | METHODS AND MATERIALS FOR THE GENERATION OF REGULATORY T CELLS - Methods are disclosed for the generation of immunosuppressive regulatory T cells. The methods can include contacting a population of CD4+CD25− T cells with a T cell receptor (TCR)/CD3 activator, a TCR co-stimulator activator, and rapamycin. Kits for the generation of immunosuppressive regulatory T cells, methods of use, and cell populations are also disclosed. | 2010-03-18 |
20100068194 | COMPOSITION FOR IN VIVO TRANSPLANTATION FOR TREATMENT OF HUMAN CERVICAL CANCER COMPRISING MONONUCLEAR CELLS DERIVED FROM UMBILICAL CORD BLOOD - Provided is a composition for in vivo transplantation for the treatment of human cervical cancer, comprising mononuclear cells derived from umbilical cord blood and a pharmaceutically acceptable carrier. When the umbilical cord blood-derived mononuclear cells are transplanted in vivo, cervical cancer can be effectively treated. In particular, the mononuclear cells derived from the umbilical cord blood retain high differentiation and proliferation abilities and exhibit very low graft-versus-host (GVH) reactions which are side effects caused by transplantation, and thus, can be transplanted to many patients. | 2010-03-18 |
20100068195 | Manufacture of Active Highly Phosphorylated Human Lysosomal Sulfatase Enzymes and Uses Thereof - This invention provides compositions of active highly phosphorylated lysosomal sulfatase enzymes, their pharmaceutical compositions, methods of producing and purifying such lysosomal sulfatase enzymes and compositions and their use in the diagnosis, prophylaxis, or treatment of diseases and conditions, including particularly lysosomal storage diseases that are caused by, or associated with, a deficiency in the lysosomal sulfatase enzyme. | 2010-03-18 |
20100068196 | METHOD OF MICRONIZATION - A method for micronization of a dispersion of particles including a protein having a predetermined level of biological activity, is provided. The method includes introducing the dispersion into a vortex chamber milling apparatus under milling conditions which result in a protein powder having a particle size distribution of 5 to 100 μm and/or exhibiting a 30 to 400 fold size reduction of the protein particle dispersion from its original size, and retaining at least 80% of the predetermined level of biological activity of the protein. The milling conditions include one or more parameters selected from the following: input pressure between 1 and 7 Bars; injector pressure between 0.2 and 5 Bars; loading rate between 0.1 and 5 kg/hour; and gas flow between 30 and 100 m | 2010-03-18 |
20100068197 | PHARMACEUTICAL COMPOUNDS AS INHIBITORS OF CELL PROLIFERATION AND THE USE THEREOF - Disclosed are compounds of Formula I effective as cytotoxic agents. The compounds of this invention are useful in the treatment of a variety of clinical conditions in which uncontrolled growth and spread of abnormal cells occurs. | 2010-03-18 |
20100068198 | TARGETING OF ALPHA-1 OR ALPHA-3 SUBUNIT OF NA+, K+-ATPASE IN THE TREATMENT OF PROLIFERATIVE DISEASES - Targeting of select subunits of the Na | 2010-03-18 |
20100068199 | PCSK9 ANTAGONISTS - The present invention provides antagonizing antibodies, antigen-binding portions thereof, and aptamers that bind to proprotein convertase subtilisin kexin type 9 (PCSK9). Also provided are antibodies directed to peptides, in which the antibodies bind to PCSK9. The invention further provides a method of obtaining such antibodies and antibody-encoding nucleic acid. The invention further relates to therapeutic methods for use of these antibodies and antigen-binding portions thereof to reduce LDL-cholesterol levels and/or for the treatment and/or prevention of cardiovascular disease, including treatment of hypercholesterolemia. | 2010-03-18 |
20100068200 | Methods and Compositions for Inhibiting Atherosclerosis and Vascular Inflammation - Disclosed herein are compositions and methods for reducing inflammation associated with atherosclerosis and/or vascular inflammatory disease. The methods include administering to a subject in need of treatment for atherosclerosis and/or vascular inflammation a pharmaceutically effective amount of an inhibitor of the receptor activity of the S1P2 receptor. Also included are compositions including an S1P2 receptor antagonist and a pharmaceutically acceptable excipient. | 2010-03-18 |
20100068201 | COMPOSITIONS AND METHODS FOR THE SYSTEMIC TREATMENT OF ARTHRITIS - The present invention includes compositions and methods for treating arthritic joints found in patients with autoinflammation, e.g., systemic onset juvenile idiopathic arthritis, by administering at the site of inflammation a therapeutically effective amount of at least one agent that reduces or blocks the bioavailability of interleukin-1β. | 2010-03-18 |
20100068202 | METHOD OF TREATING HEMOLYTIC DISEASE - Paroxysmal nocturnal hemoglobinuria or other hemolytic diseases are treated using a compound which binds to or otherwise blocks the generation and/or the activity of one or more complement components, such as, for example, a complement-inhibiting antibody. | 2010-03-18 |
20100068203 | 17-Oxymacbecin Derivatives and Their Use in the Treatment of Cancer and/or B-Cell Malignancies - The present invention relates to 17-oxymacbecin analogues that are useful, e.g. in the treatment of cancer, B-cell malignancies, malaria, fungal infection, diseases of the central nervous system and neurodegenerative diseases, diseases dependent on angiogenesis, autoimmune diseases and/or as a prophylactic pretreatment for cancer. The present invention also provides methods for the production of these compounds and their use in medicine, in particular in the treatment and/or prophylaxis of cancer or B-cell malignancies. | 2010-03-18 |
20100068204 | 4-ARYLOXYQUINOLIN-2(1H)-ONES AS MTOR KINASE AND PI3 KINASE INHIBITORS, FOR USE AS ANTI-CANCER AGENTS - Compounds of the formula I | 2010-03-18 |
20100068205 | Methionine Sulfoxide Antibodies - Antibodies specific for methionine sulfoxide residues on proteins are provided. The antibodies are prepared using methionine-rich zein proteins, which are oxidized, as antigens. | 2010-03-18 |